{
    "clinical_study": {
        "@rank": "141146", 
        "arm_group": [
            {
                "arm_group_label": "Prospective Cohort", 
                "description": "Any woman who is pregnant, and was exposed to at least one dose of armodafinil or modafinil within 6 weeks prior to conception and/or during pregnancy\nThe condition of the fetus has not been assessed through prenatal testing such as targeted ultrasound and amniocentesis.\nEligible patients may include those where the condition of the fetus was already assessed as normal through early prenatal testing to determine the gestational age or viability within 10 weeks or less from registration."
            }, 
            {
                "arm_group_label": "Retrospective Cohort", 
                "description": "Any woman who is pregnant, and was exposed to at least one dose of armodafinil or modafinil within 6 weeks prior to conception and/or during pregnancy\nThe condition of the fetus has been assessed through prenatal testing such as targeted ultrasound or amniocentesis."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the Nuvigil/Provigil Pregnancy Registry is to characterize the\n      pregnancy and fetal outcomes associated with Nuvigil and Provigil exposure during pregnancy."
        }, 
        "brief_title": "The Nuvigil and Provigil Pregnancy Registry", 
        "completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Narcolepsy", 
            "Obstructive Sleep Apnea", 
            "Shift Work Sleep Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Narcolepsy", 
                "Sleep Apnea Syndromes", 
                "Sleep Disorders", 
                "Parasomnias", 
                "Sleep Apnea, Obstructive", 
                "Sleep Disorders, Circadian Rhythm"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Reported exposure to Nuvigil (armodafinil) and/or brand or generic formulations of\n             Provigil (modafinil) within 6 weeks of becoming pregnant, or during pregnancy\n\n          -  Able and willing to provide informed consent\n\n          -  Able and willing to provide healthcare professional and secondary contact\n             information, and for the patient herself to be contacted periodically by Registry\n             staff\n\n        Exclusion Criteria:\n\n          -  Patients who refuse to provide oral or written informed consent\n\n          -  Patients not exposed to armodafinil or brand or generic formulation of modafinil\n\n          -  Pregnancy from outside the United States"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The Registry is designed for open enrollment of all patients who meet the inclusion\n        criteria. The function and activities of the Nuvigil/Provigil Pregnancy Registry will be\n        publicized through direct mailings to obstetricians and pharmacists.  Known prescribers\n        identified from marketing sources will be targeted for Registry awareness.  A toll-free\n        phone line will be established for patient enrollment and a website containing information\n        about the Registry for both physician and patient recruitment will be available.  The\n        Registry will be posted on the FDA website for pregnancy registries, with a direct link to\n        a Nuvigil/Provigil Registry website.  For ongoing awareness, information on the Registry\n        will be included in the prescribing information and in the Medication Guides distributed\n        by the pharmacist at the time of dispensing.  In addition, patient support groups or\n        condition-related sources of information may be targeted to raise patient awareness of the\n        Registry."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792583", 
            "org_study_id": "C10953/9022"
        }, 
        "intervention": {
            "arm_group_label": [
                "Prospective Cohort", 
                "Retrospective Cohort"
            ], 
            "intervention_name": "Modafinil/armodafinil", 
            "intervention_type": "Drug", 
            "other_name": [
                "Provigil", 
                "Nuvigil"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Modafinil"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "pregnancy", 
        "lastchanged_date": "February 27, 2014", 
        "link": [
            {
                "url": "http://www.fda.gov/ScienceResearch/SpecialTopics/WomensHealthResearch/ucm134848.htm"
            }, 
            {
                "url": "http://www.provigilpregnancyregistry.com"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Horsham", 
                    "country": "United States", 
                    "state": "Pennsylvania"
                }, 
                "name": "Teva Pregnancy Registry"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Nuvigil (Armodafinil) Tablets [C-IV]/Provigil (Modafinil) Tablets [C-IV] Pregnancy Registry", 
        "overall_contact": {
            "last_name": "Registry Call Center", 
            "phone": "866-404-4106"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2019", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary objective is to characterize the pregnancy, fetal and newborn outcomes associated with Nuvigil (armodafinil) or (modafinil) exposure during pregnancy. Overall pregnancy outcome consists of any major congenital defects, alterations in fetal growth (including constitutionally small and large for gestational age infants, as well as growth-restricted infants), spontaneous losses, live births, fetal deaths and elective termination.", 
                "measure": "Overall pregnancy outcome", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and End of pregnancy"
            }, 
            {
                "description": "This consists of any adverse fetal outcomes or congenital anomalies that may be attributable to pregnancy exposure to Nuvigil or Provigil.", 
                "measure": "Adverse fetal outcomes or congenital anomalies", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and End of Pregnancy"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792583"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "This will be a listing of all all congenital defects reported (major and minor).", 
                "measure": "Congenital defects reported", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and End of pregnancy"
            }, 
            {
                "description": "This will be a complete listing of all adverse pregnancy and neonatal outcomes.", 
                "measure": "Adverse pregnancy and neonatal outcomes", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline and End of pregnancy"
            }
        ], 
        "source": "Teva Pharmaceutical Industries", 
        "sponsors": {
            "collaborator": {
                "agency": "United BioSource Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Teva Pharmaceutical Industries", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2009", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "February 2014"
    }
}